Analytical Data
-
Gene name
ABCB1
- Application
-
Alternative Names
ATP-binding cassette sub-family B member 1;P-glycoprotein 1; CD243
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08183
-
Expression Region
236-297aa
-
Molecular Weight
10.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABCB1, also known as P-glycoprotein, is a key member of the ATP-binding cassette (ABC) transporter family, playing a crucial role in the pharmacokinetics and bioavailability of numerous drugs. Its expression is often associated with multidrug resistance (MDR) in cancer cells, where it actively mediates the efflux of a variety of therapeutic agents, thereby reducing their intracellular concentrations and efficacy. Understanding the structure and function of ABCB1 is essential for developing strategies to overcome MDR, improve drug delivery, and enhance treatment outcomes in cancer therapy. The study of recombinant ABCB1 proteins has gained significant attention in recent years, as it enables researchers to investigate the biochemical properties of this transporter in a controlled setting. By expressing recombinant ABCB1 in heterologous systems, such as yeast or mammalian cells, scientists can elucidate its substrate specificity, regulatory mechanisms, and interactions with inhibitors and potentiators. These insights contribute to the design of novel therapeutics that can circumvent ABCB1-mediated drug resistance and offer improved clinical efficacy. Furthermore, recombinant ABCB1 models serve as valuable tools for high-throughput screening of drug candidates and for studying the intricacies of drug-transporter interactions, paving the way for personalized medicine approaches in oncology and other therapeutic areas.
